# Biogen: how the business works

> For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Biogen Inc. · NASDAQ: BIIB · Sector: Health Care

Updated for Q3 FY2026 · checked Nov 20, 2026

This is the plain-text version of https://cityfort.co/stocks/biogen. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Biogen: how the business works", with the page URL.

## The 30-second summary

Biogen develops, makes and sells prescription medicines, mostly for multiple sclerosis, with $9.9 billion of revenue in FY2025. Its MS medicines face cheaper copies, and their sales fell from $4.66 billion in FY2023 to $4.04 billion in FY2025. It bought Apellis in May 2026 for about $5.3 billion, and its net debt was about $6.4 billion at Sep 30, 2026, Biogen's release says.

## 5 points

- **What it sells:** Biogen sells prescription medicines, mostly for brain and nerve diseases, and its multiple sclerosis medicines brought in $4.04 billion of its $9.9 billion FY2025 revenue. [S4]
- **Who pays it:** In FY2025, US product sales were 35.9% of Biogen's revenue, product sales outside the US 36.1%, Genentech's payments 18.8%, contract manufacturing and royalties 7.4% and the Eisai LEQEMBI share 1.8%. [S4]
- **What it keeps from $100:** Of every $100 of revenue in FY2025, Biogen kept $13.1 as net income; it reports no operating income, and its EBITDA (profit before interest, tax and wear-and-tear), a Cityfort calculation, was $26.7 per $100. [S4]
- **Where the operating profit comes from:** Biogen reports one business segment and no profit by product; multiple sclerosis medicines were 40.8% of FY2025 revenue and rare disease medicines 21.8%. [S4]
- **The one thing to watch:** Multiple sclerosis medicines brought in $919 million in Q3 FY2026, down from $1.06 billion a year earlier, while the Apellis medicines added $243 million. [S16, S1]

## What does Biogen sell?

Biogen invents, makes and sells prescription medicines, mostly for diseases of the brain and nerves. Its biggest group treats multiple sclerosis (MS), where the immune system attacks the nerves. It also earns royalties and profit shares on drugs that partners sell.

- **Multiple sclerosis medicines:** TYSABRI, VUMERITY, TECFIDERA, AVONEX and PLEGRIDY, sold to treat MS. Together they brought in $4.04 billion in FY2025, down from $4.66 billion in FY2023. [S4]
- **SPINRAZA:** A drug for spinal muscular atrophy (SMA), an inherited disease that weakens muscles. Sales were $1.55 billion in FY2025; the FDA approved a higher-dose regimen in March 2026. [S4, S1]
- **SKYCLARYS and QALSODY:** SKYCLARYS treats Friedreich ataxia, a rare inherited nerve disease, and came with the 2023 purchase of Reata. QALSODY treats a genetic form of ALS (SOD1-ALS). FY2025 sales were $520.5 million and $86.9 million. [S4, S1]
- **SYFOVRE and EMPAVELI:** Bought with Apellis in May 2026. SYFOVRE treats geographic atrophy, an immune-driven disease of the retina; EMPAVELI treats a rare blood disorder (PNH) and two kidney diseases. They sold $191.3 million and $51.5 million in Q3 FY2026. [S1, S16]
- **LEQEMBI:** An Alzheimer's antibody developed and sold with Japan's Eisai. Biogen books its 50% share of the partnership's revenue and costs, $177.7 million in FY2025. [S4, S1]
- **ZURZUVAE:** A pill for postpartum depression, sold in the US with Supernus, which takes half of the US profit or loss. Sales were $195.1 million in FY2025. [S4, S1]
- **Biosimilars:** Near-copies of other companies' biologic drugs (medicines made in living cells), such as BENEPALI and IMRALDI, sold by Biogen mostly in Europe; Samsung Bioepis makes IMRALDI. Sales were $729.1 million in FY2025. [S4, S1]
- **Anti-CD20 programs with Genentech:** A royalty on US sales of Genentech's MS drug OCREVUS ($1.41 billion in FY2025) plus a share of US profits on RITUXAN, GAZYVA and LUNSUMIO ($420.2 million). [S4]

## Who pays Biogen?

- **Wholesale and specialty distributors (US):** Buy Biogen's medicines and resell them to pharmacies and hospitals. US product revenue was $3.55 billion in FY2025, 49.8% of product revenue. [S4]
- **Health systems and distributors outside the US:** Buy its medicines in Europe, Asia and other regions: $3.57 billion of product revenue in FY2025, $1.87 billion of it from Europe outside Germany. [S4]
- **Genentech (Roche group) (18.8% of revenue):** Pays the OCREVUS royalty and Biogen's share of US profits on RITUXAN, GAZYVA and LUNSUMIO: $1.86 billion in FY2025. [S4]
- **Contract manufacturing and royalty customers (7.4% of revenue):** Companies that pay Biogen to make their drugs, or pay it other royalties: $732.9 million in FY2025. [S4]
- **Eisai (LEQEMBI partnership) (1.8% of revenue):** Biogen's 50% share of LEQEMBI revenue and costs: $177.7 million in FY2025. [S4]
- **Customer concentration:** Two wholesale distributors each bought more than 10% of Biogen's total revenue in FY2025, and together they took about 43.9% of gross product revenue, up from 36.9% in FY2023. Genentech payments were 18.8% of FY2025 revenue (Cityfort calculation from the FY2025 10-K). [S4]

## Where the money went (FY2025)

1. Customers and partners paid Biogen $9.89 billion in FY2025; $7.12 billion was for its own medicines.
2. Making and supplying the medicines took $2.40 billion.
3. Research took $2.25 billion, including $471.8 million paid for drug programs bought from others. Selling and administration took $2.43 billion.
4. Amortization of drug rights bought in past deals ($515.0 million), partners' profit shares, restructuring and write-downs took $940.3 million more. Interest and other items took $305.6 million.
5. Tax took $263.6 million, and $1.29 billion was left as net income.

Sources: S4.

## Key numbers by year (US$ million)

Financials: consolidated, US$ million. Fiscal years are the company's own: Fiscal year ends Dec 31 (the calendar year). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (US$ per share, diluted) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY2021 | 10,981.7 | — | — | 1,556.1 | 14.2% | 10.4 | 3,639.9 | 258.1 | 3,381.8 | S14 |
| FY2022 | 10,173.4 | 4,002 | 39.3% | 3,046.9 | 29.9% | 20.87 | 1,384.3 | 240.3 | 1,144 | S13, S8 |
| FY2023 | 9,835.6 | 2,107.1 | 21.4% | 1,161.1 | 11.8% | 7.97 | 1,547.2 | 277 | 1,270.2 | S12, S8 |
| FY2024 | 9,675.9 | 2,922.8 | 30.2% | 1,632.2 | 16.9% | 11.18 | 2,875.5 | 153.7 | 2,721.8 | S8, S4 |
| FY2025 | 9,890.6 | 2,642 | 26.7% | 1,292.9 | 13.1% | 8.79 | 2,204.6 | 153.8 | 2,050.8 | S4, S19 |

- EBITDA here = operating income plus depreciation and amortization (from the cash flow statement).
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of Sep 30, 2026, US$ million)

Biogen's Q3 FY2026 earnings release puts net debt, debt minus cash, at about $6.4 billion at Sep 30, 2026; its Q4 FY2025 earnings release put it at about $2.0 billion at Dec 31, 2025. [S1, S4, S16, S19]

| Item | Value |
| --- | --- |
| Total debt | 7,692 |
| Cash and investments | 1,303.9 |
| Net debt (debt minus cash) | 6,388.1 |
| Net worth (shareholders' money) | 18,922.1 |
| Debt to equity (times) | 0.41 |

- Biogen's Q3 FY2026 earnings release puts debt at about $7.7 billion and cash and cash equivalents at about $1.3 billion at Sep 30, 2026. The Q3 FY2026 10-Q shows $7,292.0 million of notes payable plus a $400.0 million current portion of notes and term loan, and no marketable securities that day.
- At Dec 31, 2025 Biogen had about $4.2 billion of cash, cash equivalents and marketable securities and about $6.3 billion of debt, its Q4 FY2025 earnings release and Q3 FY2026 10-Q state. The FY2025 10-K shows $6,286.8 million of notes.
- Biogen paid for Apellis with cash and marketable securities, a $2.0 billion term loan and a $400.0 million draw on its revolving credit line, the Q3 FY2026 10-Q says.
- It also took over Apellis's term loan with Sixth Street Lending Partners, about $395.2 million including interest and prepayment fees, and repaid it in full in Q2 FY2026.
- At Dec 31, 2025 Biogen's seven series of notes carried interest rates from 2.250% (due 2030) to 6.450% (due 2055). Interest expense was $267.5 million in FY2025.
- Of the $6,567.3 million of note principal at Dec 31, 2025, none was due from 2026 to 2029, $1,500.0 million was due in 2030 and $5,067.3 million in 2031 or later, the FY2025 10-K shows.
- Goodwill and intangible assets were $20.4 billion, 63.6% of total assets of $32.1 billion at Sep 30, 2026. Debt was 0.41 times equity. Both are Cityfort calculations from the Q3 FY2026 10-Q.

## Who owns Biogen? (as of Apr 21, 2026)

Biogen has one class of stock with one vote per share, and no holder controls it. The 20 directors and executive officers held 259,975 shares plus 107,827 options and stock units, about 0.2% (Cityfort calculation from the 2026 proxy statement, record date Apr 21, 2026). [S15, S1]

- Officers and directors (as a group), shares: 0.2%

| Class | Shares (millions) | Votes per share | % of shares | % of votes | Traded | Sources |
| --- | --- | --- | --- | --- | --- | --- |
| Common stock (147,820,223 shares on Oct 26, 2026 (Q3 FY2026 10-Q cover). Biogen has one class of common stock.) | 147.82 | 1 | — | — | Yes | S1 |

Holders of 5% or more (each row shows the date of its own filing):

| Holder | Shares | Votes | As of | Note | Sources |
| --- | --- | --- | --- | --- | --- |
| PRIMECAP Management Company | 10.1% | — | Nov 13, 2025 | Proxy figure from a Schedule 13G/A filed Nov 13, 2025 (14,954,697 shares on Sep 30, 2025). | S15 |
| BlackRock, Inc. | 8.5% | — | Apr 17, 2025 | Proxy figure from a Schedule 13G/A filed Apr 17, 2025 (12,506,681 shares). This is older data. | S15 |
| FMR LLC | 6.4% | — | Feb 5, 2026 | Proxy figure from a Schedule 13G filed Feb 5, 2026 (9,413,062 shares on Dec 31, 2025). | S15 |
| State Street Corporation | 5.0% | — | Nov 10, 2025 | Proxy figure from a Schedule 13G filed Nov 10, 2025 (7,321,168 shares). | S15 |

## What could go wrong

### MS medicines losing sales to copies

Generic TECFIDERA is sold at deep discounts, and a TYSABRI biosimilar was approved in 2023. MS revenue fell from $4.66 billion in FY2023 to $4.04 billion in FY2025; Biogen said in its FY2025 10-K (Feb 6, 2026) that it expects MS revenue to keep declining. [S4, S16]

What to watch: Quarterly MS revenue: $919 million in Q3 FY2026, against $1.06 billion a year earlier.

### OCREVUS royalty halves when a biosimilar arrives

The OCREVUS royalty was $1.41 billion in FY2025, 14.3% of revenue (Cityfort calculation from the FY2025 10-K). The tiered royalty on US OCREVUS sales falls by 50% once the first FDA-approved OCREVUS biosimilar launches; the $1.41 billion also includes a 3% royalty on OCREVUS sales outside the US. [S4, S1]

What to watch: Any FDA approval of an OCREVUS biosimilar.

### Patent challenge to SPINRAZA

SPINRAZA was 15.6% of FY2025 revenue. Biogen has sued Somerset and Cipla over SPINRAZA patents, and trial is scheduled for May 2028. [S4, S1]

What to watch: Court rulings in the Delaware SPINRAZA cases.

### Debt and integration after Apellis

Biogen's earnings releases put net debt at about $2.0 billion at Dec 31, 2025 and about $6.4 billion at Sep 30, 2026. Apellis integration restructuring cost about $194.7 million in the first nine months of 2026. [S1, S4, S22, S19, S16]

What to watch: Debt repayment and SYFOVRE sales, which set whether up to $4.00 per right is paid to former Apellis holders.

### US drug price rules

The Inflation Reduction Act lets Medicare negotiate prices for some high-cost drugs: Part D from 2026 and Part B from 2028. Biogen's 10-Q also notes US actions on MFN (most-favored-nation) pricing that have been issued or proposed. [S1]

What to watch: Any Biogen medicine named for Medicare price negotiation in its filings.

### Drug trials may fail

Growth depends on new drugs. Biogen expensed $471.8 million on acquired research programs in FY2025 and $283.8 million in Q3 FY2026 alone. [S4, S16]

What to watch: Phase 3 lupus results for litifilimab, due in the first half of December 2026, the company said.

### Two distributors take a large share

Two wholesale distributors together accounted for about 43.9% of gross product revenue in FY2025. [S4]

What to watch: This share in the next 10-K.

## What to watch

Next: Q4 FY2026 results, Date not announced yet.

- **Lupus trial results:** Biogen said on Oct 28, 2026 that Phase 3 results for litifilimab in lupus (TOPAZ-1 and TOPAZ-2) are due in the first half of December 2026.
- **MS sales each quarter:** MS medicines brought in $919 million in Q3 FY2026, against $1.06 billion a year earlier. Biogen said in its FY2025 10-K that it expects MS revenue to keep declining.
- **An OCREVUS biosimilar:** Once the first FDA-approved OCREVUS biosimilar launches, the tiered royalty on US OCREVUS sales falls by 50%. The OCREVUS royalty was $1.41 billion in FY2025.
- **SYFOVRE sales and debt:** SYFOVRE sold $191.3 million in Q3 FY2026, and its sales set whether former Apellis holders get up to $4.00 more per share. Net debt was about $6.4 billion at Sep 30, 2026.

## Sources

- S1: Form 10-Q for Q3 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/875045/000087504526000096/0000875045-26-000096-index.htm (published Oct 28, 2026)
- S2: Form 10-Q for Q2 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/875045/000087504526000075/0000875045-26-000075-index.htm (published Jul 29, 2026)
- S3: Form 10-Q for Q1 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/875045/000087504526000045/0000875045-26-000045-index.htm (published Apr 29, 2026)
- S4: Form 10-K for FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/0000875045-26-000013-index.htm (published Feb 6, 2026)
- S5: Form 10-Q for Q3 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/875045/000087504525000049/0000875045-25-000049-index.htm (published Oct 30, 2025)
- S6: Form 10-Q for Q2 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/875045/000087504525000033/0000875045-25-000033-index.htm (published Jul 31, 2025)
- S7: Form 10-Q for Q1 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/875045/000087504525000018/0000875045-25-000018-index.htm (published May 1, 2025)
- S8: Form 10-K for FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/875045/000087504525000009/0000875045-25-000009-index.htm (published Feb 12, 2025)
- S9: Form 10-Q for Q3 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/875045/000087504524000032/0000875045-24-000032-index.htm (published Oct 30, 2024)
- S10: Form 10-Q for Q2 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/875045/000087504524000025/0000875045-24-000025-index.htm (published Aug 1, 2024)
- S11: Form 10-Q for Q1 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/875045/000087504524000016/0000875045-24-000016-index.htm (published Apr 24, 2024)
- S12: Form 10-K for FY2023. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/875045/000087504524000009/0000875045-24-000009-index.htm (published Feb 14, 2024)
- S13: Form 10-K for FY2022. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/875045/000087504523000009/0000875045-23-000009-index.htm (published Feb 15, 2023)
- S14: Form 10-K for FY2021. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/875045/000087504522000007/0000875045-22-000007-index.htm (published Feb 3, 2022)
- S15: Proxy statement (DEF 14A) for the 2026 annual meeting. Biogen Inc. (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/875045/000119312526187303/d788083ddef14a.htm (published Apr 28, 2026)
- S16: Q3 FY2026 earnings release (Form 8-K, Exhibit 99.1). Biogen Inc. (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/875045/000087504526000094/exhibit991-q32026pressrele.htm (published Oct 28, 2026)
- S17: Q2 FY2026 earnings release (Form 8-K, Exhibit 99.1). Biogen Inc. (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/875045/000087504526000073/exhibit991-q22026pressrele.htm (published Jul 29, 2026)
- S18: Q1 FY2026 earnings release (Form 8-K, Exhibit 99.1). Biogen Inc. (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/875045/000087504526000042/exhibit991-q12026pressrele.htm (published Apr 29, 2026)
- S19: Q4 FY2025 earnings release (Form 8-K, Exhibit 99.1). Biogen Inc. (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/875045/000087504526000011/exhibit991-q42025pressrele.htm (published Feb 6, 2026)
- S20: Q4 FY2024 earnings release (Form 8-K, Exhibit 99.1). Biogen Inc. (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/875045/000087504525000004/exhibit991-q42024pressrele.htm (published Feb 12, 2025)
- S21: Form 8-K: merger agreement with Apellis Pharmaceuticals. Biogen Inc. (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/875045/000119312526134889/d14986d8k.htm (published Mar 31, 2026)
- S22: Form 8-K: Apellis acquisition completed, CVR agreement and credit agreement. Biogen Inc. (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/875045/000119312526222908/d109852d8k.htm (published May 14, 2026)
- S23: Form 8-K: board chair change (Items 5.02 and 8.01). Biogen Inc. (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/875045/000119312526046803/d937279d8k.htm (published Feb 11, 2026)
